Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly Dividend Announcement
• Eli Lilly announced a quarterly dividend of $1.30 per ordinary share which will be made payable on 2024-12-10. Ex dividend date: 2024-11-15
• Eli Lilly annual dividend for 2024 was $5.20
• Eli Lilly annual dividend for 2023 was $4.52
• Eli Lilly's trailing twelve-month (TTM) dividend yield is 0.63%
• Eli Lilly's payout ratio for the trailing twelve months (TTM) is 54.12%
• Eli Lilly's dividend growth over the last five years (2018-2023) was 14.97% year
• Eli Lilly's dividend growth over the last ten years (2013-2023) was 8.71% year
Eli Lilly Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-15 | $1.30 | quarterly | 2024-12-10 |
2024-08-15 | $1.30 | quarterly | 2024-09-10 |
2024-05-15 | $1.30 | quarterly | |
2024-02-14 | $1.30 | quarterly | 2024-03-08 |
2023-11-14 | $1.13 | quarterly | 2023-12-08 |
2023-08-14 | $1.13 | quarterly | 2023-09-08 |
2023-05-12 | $1.13 | quarterly | 2023-06-09 |
2023-02-14 | $1.13 | quarterly | 2023-03-10 |
2022-11-14 | $0.98 | quarterly | 2022-12-09 |
2022-08-12 | $0.98 | quarterly | 2022-09-09 |
2022-05-13 | $0.98 | quarterly | 2022-06-10 |
2022-02-14 | $0.98 | quarterly | 2022-03-10 |
2021-11-12 | $0.85 | quarterly | 2021-12-10 |
2021-08-12 | $0.85 | quarterly | 2021-09-10 |
2021-05-13 | $0.85 | quarterly | 2021-06-10 |
2021-02-11 | $0.85 | quarterly | 2021-03-10 |
2020-11-12 | $0.74 | quarterly | 2020-12-10 |
2020-08-13 | $0.74 | quarterly | 2020-09-10 |
2020-05-14 | $0.74 | quarterly | 2020-06-10 |
2020-02-13 | $0.74 | quarterly | 2020-03-10 |
2019-11-14 | $0.65 | quarterly | 2019-12-10 |
2019-08-14 | $0.65 | quarterly | 2019-09-10 |
2019-05-16 | $0.65 | quarterly | 2019-06-10 |
2019-02-14 | $0.65 | quarterly | 2019-03-08 |
2018-11-14 | $0.56 | quarterly | 2018-12-10 |
2018-08-14 | $0.56 | quarterly | 2018-09-10 |
2018-05-16 | $0.56 | quarterly | 2018-06-08 |
2018-02-14 | $0.56 | quarterly | 2018-03-09 |
2017-11-14 | $0.52 | quarterly | 2017-12-08 |
2017-08-11 | $0.52 | quarterly | 2017-09-08 |
2017-05-11 | $0.52 | quarterly | 2017-06-09 |
2017-02-13 | $0.52 | quarterly | 2017-03-10 |
2016-11-10 | $0.51 | quarterly | 2016-12-09 |
2016-08-11 | $0.51 | quarterly | 2016-09-09 |
2016-05-11 | $0.51 | quarterly | 2016-06-10 |
2016-02-10 | $0.51 | quarterly | 2016-03-10 |
2015-11-10 | $0.50 | quarterly | 2015-12-10 |
2015-08-12 | $0.50 | quarterly | 2015-09-10 |
2015-05-14 | $0.50 | quarterly | 2015-06-10 |
2015-02-11 | $0.50 | quarterly | 2015-03-10 |
2014-11-12 | $0.49 | quarterly | 2014-12-10 |
2014-08-13 | $0.49 | quarterly | 2014-09-10 |
2014-05-13 | $0.49 | quarterly | 2014-06-10 |
2014-02-12 | $0.49 | quarterly | 2014-03-10 |
2013-11-13 | $0.49 | quarterly | 2013-12-10 |
2013-08-13 | $0.49 | quarterly | 2013-09-10 |
2013-05-14 | $0.49 | quarterly | 2013-06-10 |
2013-02-13 | $0.49 | quarterly | 2013-03-08 |
Eli Lilly Dividend per year
Eli Lilly Dividend growth
Eli Lilly Dividend Yield
Eli Lilly current trailing twelve-month (TTM) dividend yield is 0.63%. Interested in purchasing Eli Lilly stock? Use our calculator to estimate your expected dividend yield:
Eli Lilly Financial Ratios
Eli Lilly Dividend FAQ
Other factors to consider when evaluating Eli Lilly as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Eli Lilly stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Eli Lilly's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Eli Lilly publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Eli Lilly distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Eli Lilly are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Eli Lilly sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Eli Lilly distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Eli Lilly declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Eli Lilly's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Eli Lilly's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.